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Abstract
Background: Preanalytical variables, such as sample 
collection, handling and transport, may affect patient 
results. Preanalytical phase quality monitoring should 
be established in order to minimize laboratory errors and 
improve patient safety.
Methods: A retrospective study (2001–2013) of the results 
obtained through the Spanish Society of Clinical Bio-
chemistry and Molecular Pathology (SEQC) External 
quality assessment (preanalytical phase) was performed 
to summarize data regarding the main factors affecting 
preanalytical phase quality. Our aim was to compare data 
from 2006 to 2013 with a previously published manuscript 
assessing the 2001–2005 period.
Results: A significant decrease in rejection rates was 
observed both for blood and urine samples. For serum 
samples, the most frequent rejection causes in the first 
period were non-received samples (37.5%), hemolysis 
(29.3%) and clotted samples (14.4%). Conversely, in the 
second period, hemolysis was the main rejection cause 
(36.2%), followed by non-received samples (34.5%) and 
clotted samples (11.1%). For urine samples, the main 
rejection cause overall was a non-received sample (up to 
86.1% of cases in the second period, and 81.6% in the 
first). For blood samples with anticoagulant, the number 
of rejections also decreased. While plasma-citrate-
ESR still showed the highest percentages of rejections 
(0.980% vs. 1.473%, p < 0.001), the lowest corresponded 
to whole-blood EDTA (0.296% vs. 0.381%, p < 0.001).
Conclusions: For the majority of sample types, a decrease 
in preanalytical errors was confirmed. Improvements in 
organization, implementation of standardized procedures 
in the preanalytical phase, and participation in a Span-
ish external quality assessment scheme may have notably 
contributed to error reduction in this phase.
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Introduction
Scientific evidence supports the theory that most labora-
tory errors take place in the preanalytical phase, where 
processes are mostly manual and with little or no stand-
ardization [1–4]. Such processes involve different health-
care and non-healthcare professionals, as well as patients 
themselves. The fulfillment of these processes by organi-
zations or individuals not directly dependent on the 
laboratory is considered to be a cause of increased error 
probability, and in turn hinders error detection, control 
and monitoring. Given that laboratory results have a sig-
nificant impact in clinical decisions, the implication of 
such errors in patient safety may be highly relevant [5–9]. 
Accordingly, the improvement of preanalytical processes 
is currently one of the greatest challenges in laboratory 
medicine. The establishment of internal quality monitor-
ing systems and participation in external peer compari-
son programs represent essential tools for the continuing 
improvement of these processes, as crucial as quality 
improvement of analytical processes used to be.
The American College of Pathologists was the first 
organization to perform external quality evaluation pro-
grams in the preanalytical phase (Q-probes, Q-tracks), and 
their results are periodically published. Every program 
includes several variables from both the preanalytical and 
the postanalytical phase [10–14]. The Spanish Society of 
Clinical Biochemistry and Molecular Pathology (SEQC) has 
extensive experience in the organization of external quality 
programs for the analytical phase and is aware of the rel-
evance of preanalytical errors. Consequently, in 1998, it 
decided to start a pilot program for quality assurance of the 
preanalytical phase, which was consolidated later in 2001. 
The main objective of that program was to offer an easy tool 
for detecting the most frequent errors in the preanalytical 
phase to all Spanish clinical laboratories, so as to promote 
cross-comparison of results and thus stimulate continu-
ous improvement. The implementation of these programs 
is increasingly becoming a priority worldwide given that 
the ISO 15189:2012 requires participation in “interlabora-
tory comparison programs”. Subsequently, other programs 
assessing different aspects of the preanalytical phase have 
been developed [15–19], but are still scarce.
The program developed by the Commission on Quality 
Assurance in the Extraanalytical phase of the SEQC 
focused until 2013 on the analysis of the causes of sample 
rejection and included four cycles per year, collecting 
information on blood samples in two cycles and on urine 
samples in the other two. Participants were asked to reg-
ister the number of and causes for rejections of routine 
or stat samples. The main objective of this program was 
to assess, for each laboratory, the frequency and type of 
sample errors (rejections) that occurred in the preanalyti-
cal phase, attributable to blood drawing, manipulation 
and collection. A rejection can be considered when one 
or several results cannot be delivered to a clinician due to 
causes related to preanalytical errors.
The information provided by laboratories (expressed 
as absolute number and type of rejection depending on 
sample type) was statistically analyzed, comparing indi-
vidual laboratory results with the global results obtained 
from all participating laboratories. This information was 
later sent to every laboratory, for analysis of their own 
results, verification of objective achievement, and imple-
mentation of pertinent improvement actions.
The results for the first 5 years of the program (2001–
2005) for blood and urine samples were published in 2006 
and 2008, respectively [20, 21]. A retrospective analysis of 
the results (rejected specimens) obtained for blood and 
urine over the last 13 years (2001–2013) of the program is 
herein presented.
Materials and methods
The results (rejected specimens) have been divided into two periods: 
those obtained from 2001 to 2005 and those obtained from 2006 to 2013.
Design
Twice a year (March and October), the participants sent to the pro-
gram the first 100 rejected blood samples, and twice a year (May 
and November) the first 50 rejected samples of urine produced each 
month, together with the total number of blood and urine samples 
processed during the period. If the first 100 rejected blood samples 
or the first 50 urine samples were obtained in a period of <1 month, 
only samples received in the period up to day of the threshold num-
ber for rejected samples were counted. In contrast, if in 1 month 100 
blood samples or 50 urine sample rejections were not obtained, the 
total monthly data were counted. Table 1 shows the sample types and 
rejection causes for blood and urine (evaluated variables).
Program objective
The main objective was to evaluate the existing status of preanalyti-
cal phase quality and to obtain information allowing for identifica-
tion and quantification of the most frequently found errors in this 
phase. The organization focused on the study of rejected specimens 
and reasons for their rejection.
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Definition of a rejection
A rejection can be considered when one result (or several results) 
cannot be delivered to a clinician due to causes attributable to prean-
alytical errors: test not performed or reported, as the specimen does 
not meet laboratory acceptability criteria. Rejections due to either 
lipidemia or icterus were not considered.
Statistics
All data were analyzed with the Statistical Package SPSS (SPSS Inc., 
Chicago, IL, USA). The following calculations were performed:
 – Calculation of the percentage of rejected samples, by comparing 
them to the total number of samples according to (A) sample 
type, (B) reason for rejection, and (C) sample type and reason 
for rejection.
 – Calculation of the percentage of rejected samples compared to 
all registered rejections for blood and for urine, respectively, 
according to rejection causes.
 – Percentage of laboratories according to rejection rates.
To evaluate whether differences were statistically significant between 
periods, a χ2-test was used to compare the rejection rates depending 
on sample type and rejection causes individually and together. Sta-
tistical significance was set at 0.05.
Results
In the first period (2001–2005) up to 105 laboratories were 
included [21], with a total of 433 participations, while in 
the second period (2006–2013), this increased to 121 labo-
ratories with 585 participations.
Table 1: Sample types and rejection causes for blood and urine.
Blood Urine








Clotted sample Not received concurrent 
24 h-urine sample
Sample not received Sample not received
Insufficient sample Insufficient sample
Hemolyzed sample Inadequate labeling
Wrong container Wrong container




Other reasons Other reasons
For blood samples, a global rejection rate of 0.699% 
was detected (32,977 rejections in 4,715,132 samples) 
during the first period. When comparing the second 
period with the first, a significant reduction in the rejec-
tion rate was observed (0.488% vs. 0.699 p < 0.001). In the 
second period, 49,134 rejections were listed from among 
10,060,666 samples (Table 2).
In both periods, the sample types with the lowest rejec-
tion rates were EDTA whole blood and serum (Table 2). For 
all blood sample types, the rejection rate decreased sig-
nificantly when both periods were compared, except for 
plasma and whole-blood heparin where the rejection rate 
significantly increased. For urine samples, there was a 
similar decrease in the rejection rates in the second period 
(1.26% vs. 1.96%, p < 0.001) (Table 2).
In both periods, the most frequent sample overall is 
serum (45.7% and 49.3%, first and second period, respec-
tively), followed by whole-blood EDTA (29.8% and 33.4%). 
The number of citrate erythrocyte sedimentation rate (ESR) 
samples substantially decreased, from 10.83% to 3.94%.
In Figure 1A and B, the distribution of participants is 
shown according to the rejection rate for both periods, for 
blood and urine samples, respectively. When both periods 
were compared, the percentage of laboratories with a 
blood sample rejection rate below 0.5% increased (34.7% 
vs. 27.4%). The same phenomenon was observed in urine 
samples: in the second period, the percentage of laborato-
ries with a rejection rate below 1% is also higher than in 
the first period (28.9% vs. 17.9%).
For serum samples, the main rejection cause in the 
second period was hemolysis (36.2%), followed by non-
received samples (34.5%) (Figure 2A). However, observa-
tions were reversed in the first period: the most frequent 
cause was non-received samples (37.5%), followed by 
hemolysis (29.3%). In both periods, the third cause was a 
clotted sample (11.14% vs. 14.46%). For urine samples, the 
main rejection cause overall was a non-received sample: 
up to 86.1% in the second period, from 81.6% in the first 
(Figure 2B).
In Table 3, the rejection causes are shown as a per-
centage of the total number of samples. The all-cause 
rejection rate in the second period was significantly lower 
(p < 0.001), except for defective transportation, with an 
increased rate, despite representing a low prevalence. 
The greatest decrease was seen in samples with insuffi-
cient blood volume compared to anticoagulant, followed 
by clotted and non-received samples. For hemolyzed 
samples, there was a smaller decrease.
When all rejection causes are assessed depending on 
sample type, hemolysis is the most prevalent for serum 
and plasma heparin (Table 4). While serum shows a 
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Table 2: Number and percentage of rejected samples according to sample type.
Type 2001–2005 2006–2013 p-Value
Total, n Total, % Rejections, n Rejections, % Total, n Total, % Rejections, n Rejections, %
Serum 2,157,487 45.76 13,048 0.605 4,962,818 49.33 21,724 0.438 <0.001
ESR citrate 510,739 10.83 7522 1.473 396,824 3.94 3889 0.980 <0.001
Coagulation citrate 431,942 9.16 5030 1.165 777,643 7.73 7402 0.952 <0.001
Plasma heparin 122,118 2.59 1209 0.990 374,227 3.72 4062 1.085 <0.005
Whole-blood EDTA 1,404,941 29.80 5358 0.381 3,364,084 33.44 9943 0.296 <0.001
Whole-blood heparin 87,905 1.86 810 0.921 185,070 1.84 2114 1.142 <0.001
Total blood 4,715,132 32,977 0.699 10,060,666 49,134 0.488 <0.001
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Figure 1: Distribution of participations.
(A) Distribution of participations according to rejection rate (blood). (B) Distribution of participations according to rejection rate (urine).
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(A) Rejection causes expressed as percentages and compared to all registered rejections (blood). (B) Rejection causes expressed as percent-
ages and compared to all registered rejections (urine).
statistically significant decrease (0.276% vs. 0.386%), con-
versely there is a significant increase in plasma heparin 
hemolysis (0.835% vs. 0.684%).
The main rejection cause in other samples was non-
reception, with a significant reduction in the second 
period for the ESR-citrate (0.450% vs. 0.561%), coagula-
tion-citrate (0.510% vs. 0.663%), and whole-blood EDTA 
(0.144% vs. 0.212%). For whole-blood heparin a statisti-
cally significant increase is observed in the second period 
(0.568% vs. 0.439%).
Discussion
These types of programs can help in identifying the exist-
ence of problems, and to stimulate corrective actions, but 
by themselves do not control anything and do not identify 
the causes of the non-conformities.
There are currently only a few external quality assess-
ment schemes for the preanalytical phase worldwide, 
which, in addition, are poorly standardized. The program 
presented herein was developed by SEQC in 1998 and 
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offered to Spanish clinical laboratories starting in 2001. 
It was based on the comparison of preanalytical errors or 
the rejection causes attributable to blood drawing, han-
dling, and sample collection.
The programs by the American College of Pathologists 
(Q-Track) and the Australian (KIMMS) are similar, since 
they are also based on the registration and peer-compar-
ison of errors (rejections) [10, 11, 13, 14, 18]. The program 
developed by the Brazilian Society of Clinical Pathology is 
based on indicator comparison, including the concept of 
rejection, but not in an exclusive way [19]. In contrast, the 
IFCC project “Laboratory Errors and Patient Safety” [22] 
offers the participating laboratories the possibility of peer-
comparison based on indicators for different processes.
In year 2008, an evaluation of our program was pub-
lished, assessing the first 5 years of functioning, from 2001 
to 2005 [21]. In the present manuscript, the study period 
is extended until 2013, with the aim of evaluating possi-
ble changes, and their impact on process improvement. 
A decrease in preanalytical errors (rejections) in partici-
pating Spanish laboratories was confirmed, for both urine 
and blood samples, with the decrease being greater for the 
latter.
The acknowledgment that the total laboratory process 
starts as soon as the physician makes a test request posed 
a shift in laboratory scientists’ thinking. This included the 
assumption that responsibility for this process is shared 
among any healthcare professionals involved in the first 
part of the process, even when located far away from the 
central laboratory itself. The declaration of such respon-
sibility, together with the verification of error production, 
led to a progressive implementation of measures aimed 
at improving quality control results in the preanalytical 
phase. Among other factors, continuous  in-service train-
ing for phlebotomists, designation of preanalytical phase 
supervisors within the clinical laboratories, and registra-
tion of detected errors in the preanalytical phase are of 
the utmost importance for the establishment of useful 
indicators for the internal control of the preanalytical 
phase.
The automation of the preanalytical process, with 
the emergence of instrumentation for sample manage-
ment and classification, as well as online communication 
with the laboratory information system, led to a gradual 
decrease in error probability [23, 24] and allowed for the 
possibility of automatic data collection and registration, 
without the need for manual registration.
The development of a feedback system between lab-
oratories and blood-collection centers, with error com-
munication and the adoption of consensus solutions is 
equally postulated as a contributing factor for improve-
ment. Certification and accreditation impose quality crite-
ria to be adopted by clinical laboratories that include the 
preanalytical phase. The implementation of such quality 
management systems is highlighted as a positive element 
in process improvement.
During the study period, an increasing interest in the 
preanalytical processes arose, as was demonstrated by the 
growing citations in PubMed (“preanalytic or pre- analytic 
or preanalytical”). In the first period, there were <200 
citations, whereas there were more than 700 in the second 
period. Moreover, SEQC has promoted the organization of 
courses and conferences so as to increase the interest of 
laboratory professionals in such topics.
When the results were analyzed based on sample type 
and reason for rejection, several factors contributing to 
this improvement were identified. Worth mentioning is 
the implementation of the electronic laboratory request, 
which includes information regarding the number and 
type of samples needed to be drawn for the correct perfor-
mance of the requested tests. This guidance for phleboto-
mists could have helped in lowering the rejections due to 
non-reception of samples.
For its part, the implementation of analyzers able to 
quantify ESR in EDTA tubes notably contributed to the 
decrease in the global rejection rate, since the formerly 
Table 3: Sample rejection rates due to different causes for two time periods, expressed as percentage of received blood samples.
2001–2005 2006–2013 Difference % p-Value
Clotted 0.101 0.054 −46.2 <0.001
Not received 0.263 0.168 −35.8 <0.001
Insufficient 0.064 0.045 −29.1 <0.001
Hemolyzed 0.205 0.177 −13.8 <0.001
Wrong container 0.013 0.009 −32.1 <0.001
Transport defect 0.002 0.003 48.7 0.001
Inappropriate sample/anticoagulant ratio 0.025 0.010 −60.3 <0.001
Others 0.027 0.022 −18.9 <0.001
Total 0.699 0.488 −30.2 <0.001
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used sample (citrate ESR) presented the highest rejection 
rate.
There is a smaller reduction of rejections due to hemol-
ysis compared to other causes due to the fact that a high 
number of participant laboratories detected hemolysis by 
means of the hemolysis index reported by biochemistry 
 analyzers (79.1%, according to our survey; data not pub-
lished) instead of visual inspection, which was the most used 
method in the first period. This automatic inspection allows 
for the detection of hemolysis below 0.3 g hemoglobin/L, 
which goes visually undetected. Nevertheless, the lack of 
harmonization of this indicator is important, both in the 
visual and the automatic methods, together with the rejec-
tion criteria of each laboratory for every hemolysis-affected 
magnitude. This phenomenon has recently been described 
elsewhere [25, 26], thus showing the need for a consensus 
regarding rejection criteria which would include serum 
indices (hemolysis, icterus, lipidemia), as currently used by 
WEQAS [18]. A recent multicenter study in several Spanish 
laboratories was performed to evaluate whether a control 
material could be used to verify the value of the serum 
indices in different analyzers [27].
The lack of standardization in data collection by the 
participating laboratories is one of the limitations of this 
study. In most laboratories, data registration is not auto-
mated, hence requiring manual registration and making 
it personnel dependent. Neither is the required activity 
for data calculation standardized, since there is no con-
sensus as to the number to which the errors will be com-
pared (number of patients, number of samples, number 
of tubes, number of laboratory requests, number of blood 
collections, etc.). In a recent study by Cornes et  al. [28] 
including the results of a survey of 157 laboratories in the 
UK, the same disparity is evidenced in the indicator calcu-
lation: up to 51% of the laboratories compared the number 
of errors to the samples requested, whereas the other 49% 
did so to the number of requests. Information systems 
often allow little access to these data, or none at all. This 
lack of standardization makes it practically impossible to 
compare our results with other publications.
Another limiting factor in result interpretation is 
the low participation in the program (similar in both 
periods). This might be due to the difficulty in obtaining 
the requested data (lack of automatic registration), thus 
making data collection tedious. In addition, the impor-
tance of inter-laboratory comparison is already known for 
the analytical phase, and should be equally understood 
for any preanalytical process. Moreover, as most preana-
lytical steps take place outside the laboratory, where the 
culture of monitoring is poorly developed, the participa-
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The difficulty in data collection and the need for 
standardization, not only in the preanalytical processes 
but also in any laboratory step, has been brought to light 
by different groups [16, 29] working in the harmonization 
of quality indicators and their establishment as a tool for 
improvement and benchmarking among different labo-
ratories, with the aim of reducing errors and enhancing 
patient safety.
In view of the different evaluations of the program, 
and considering the suggestions of participants in 
the satisfaction surveys at the end of each period, the 
program was redesigned in 2014. The main objectives 
of the new design were, on the one hand, better acces-
sibility to the program for users, enabling easier data 
collection and submission, and, on the other hand, an 
enhancement of the program’s robustness by increas-
ing the length of time for each laboratory to register 
rejections.
Participation in peer-comparison programs like the 
one described is a powerful tool, but only for promoting 
error registration and for raising awareness of their rel-
evance, or of the need for intervention if the frequency is 
much different from the median, not for error detection 
itself (the program itself does not detect errors, just regis-
ters those detected).
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